# Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

> **NCT03980925** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 37 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Neoplasm
- Gastroenteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03980925
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-11
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-06-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980925, "Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03980925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*